Send to

Choose Destination
Cancer Biol Ther. 2018 Aug 6:1-6. doi: 10.1080/15384047.2018.1491501. [Epub ahead of print]

Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma.

Author information

a Department of Radiation Oncology, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy , Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology , Guangzhou , Guangdong Province , P.R. China.
b Department of Radiation Oncology , the Fifth Affiliated Hospital of Sun Yat-sen University , Zhuhai Guangdong Province , P.R. China.
c Department of Radiation Oncology , Wuzhou Red Cross Hospital , Wuzhou , Guangxi Province , People's Republic of China.
d Department of Environmental Health Sciences , School of Public Health, University, Albany, State University of New York , Rensselaer , NY , USA.



The benefits of additional use of nimotuzumab (NTZ) in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is largely unclear. We aim to compare LA-NPC treatment outcomes in patients that received CCRT with nimotuzumab (NTZ) to patients that received CCRT only.


Between October 2009 and January 2012, 31 previously untreated and newly diagnosed LA-NPC patients were administered CCRT (3 cycles of 100 mg/m2 cisplatin every third week with intensity-modulated radiotherapy) plus NTZ according to an IRB-approved institutional research protocol. A well-balanced cohort of 62 patients who received CCRT alone was created by matching each patient who received CCRT plus NTZ via propensity-matched analysis in a 2:1 ratio.


Compared with CCRT only, CCRT plus NTZ was significantly associated with superior overall survival (5-year OS; 96.8% vs. 82.3%; P = 0.001), superior distant metastasis-free survival (5-year DMFS; 90.3% vs. 80.6%, P = 0.012) and superior progression-free survival (5-year PFS; 83.9% vs. 71.0%, P = 0.006). In multivariate analysis, the inclusion of NTZ to CCRT was confirmed to be a favorable factor for OS (HR, 0.31; 95% CI, 0.02-0.71; P = 0.027), DMFS (HR, 0.45; 95% CI, 0.13-0.77; P = 0.034), and PFS (HR, 0.38; 95% CI, 0.11-0.89; P = 0.041). In addition, no significant differences in hematology parameters, dermatitis, nausea, vomiting, xerostomia, nephrotoxicity or neurotoxicity were found between the two arms (all P > 0.05).


The inclusion of NTZ to CCRT is more effective for long-term survival among LA-NPC patients than CCRT only.


Nasopharyngeal carcinoma; acute toxicity; concurrent chemoradiotherapy; locoregionally; nimotuzumab; propensity score matching; survival

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center